Moreover, extensive data in preclinical tumor models and on-going I/II phase clinical trials in multiple tumors have shown the restoration of anti-tumor immunity by targeting Tim-3 (81), especially in combination with PD-1 blockade (82–84). Here, HAVCR2 is linked to neoplasm.